Scarica l'app Stockscreener
7.63
4.52%
0.33
Dopo l'orario di chiusura:
7.63
Precedente Chiudi:
$7.30
Aprire:
$7.61
Volume 24 ore:
24,721
Relative Volume:
1.37
Capitalizzazione di mercato:
$4.06M
Reddito:
-
Utile/perdita netta:
$-12.52M
Rapporto P/E:
-0.0631
EPS:
-120.8826
Flusso di cassa netto:
$-4.83M
1 W Prestazione:
+43.96%
1M Prestazione:
+40.65%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$7.25
$8.25
Intervallo di 1 settimana:
$5.34
$8.25
Portata 52W:
$4.3201
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Nome
Decoy Therapeutics Inc
Settore
Industria
Telefono
346-772-0346
Indirizzo
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
7.63 | 3.88M | 0 | -12.52M | -4.83M | -120.88 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-04-27 | Iniziato | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Borsa (DCOY) Ultime notizie
Decoy Therapeutics names MIT professor as advisory board chair - Investing.com
Decoy Therapeutics names MIT professor as advisory board chair By Investing.com - Investing.com Australia
Press Release: Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board - Moomoo
Decoy Therapeutics (DCOY) Surges 13.5%: Testing Key Resistance at $7.67Shared Trade Ideas - Newser
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
DCOY Sets May 22 Vote, Puts Focus Back on Thinly Traded Stock - Bez Kabli
hVIVO to host capital markets day as it pitches broader clinical development role - Yahoo Finance UK
Decoy Therapeutics Sets 2026 Annual Shareholder Meeting Date - TipRanks
Decoy Therapeutics sets date for 2026 annual meeting and proposal deadlines - Investing.com Australia
Number of shareholders of Decoy Therapeutics Inc. – NASDAQ:DCOY - TradingView
Decoy Therapeutics outlines antiviral pipeline milestones By Investing.com - Investing.com Nigeria
Certain Restricted Stock Units of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026. - marketscreener.com
Certain Stock Options of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026. - marketscreener.com
1,051,782 Common Stock of Decoy Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2026. - marketscreener.com
Decoy Therapeutics Inc. 2026 Q1 10-Q Filing: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Decoy Therapeutics: Q1 Earnings Snapshot - KTEN
Decoy Therapeutics Inc. 1Q 2026: Net loss $(2.22M), EPS $(4.18) — 10-Q Summary - TradingView
Decoy Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
DCOY Q1'26 Earnings: EPS estimate is (4.12) USD - TradingView
Decoy Therapeutics to implement 1-for-12 reverse stock split - Investing.com
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston - BioSpace
Decoy Therapeutics (DCOY) Proxy Filing Summary - Quartr
Decoy Therapeutics Inc (FRA:FP11) Stock PDF (Updated: 2026/04/27) - GuruFocus
Decoy Therapeutics Showcases Novel Antiviral Therapies in Boston - Intellectia AI
Decoy Therapeutics Inc (FRA:FP11) Stock Earnings Transcripts - GuruFocus
Salarius Pharmaceuticals stock tumbles after announcing $7 million discounted public offering - MSN
Is Decoy (DCOY) stock gaining market share | Q3 2024: EPS Tops ViewsHot Market Picks - Cổng thông tin điện tử tỉnh Lào Cai
DCOY Price Today: Decoy Therapeutics Inc. Stock Price, Quote & Chart - MEXC
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline - BioSpace
Transcript : Decoy Therapeutics Inc.Special Call - marketscreener.com
CEO Rick Pierce to outline Decoy's 2026 outlook in April 9 webcast - Stock Titan
Decoy Therapeutics outlines antiviral pipeline milestones - Investing.com
Decoy Therapeutics Launches Multi-Virus Antiviral Platform - Intellectia AI
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
What is the volatility of Decoy (DCOY) Stock | Price at $5.84, Down 0.76%Expert Momentum Signals - Newser
DCOY Technical Analysis & Stock Price Forecast - Intellectia AI
Decoy Therapeutics to Participate in Virtual Investor Closing Be - GuruFocus
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 - Finviz
Is Decoy (DCOY) Stock a Buy Now | DCOY Q4 Earnings: Beats Estimates by $25.32Expert Entry Points - Newser
Decoy Therapeutics Inc (STU:FP11) Stock Earnings Transcripts - GuruFocus
Decoy Therapeutics Inc (STU:FP11) Stock Price & 30 Year Financial Data - GuruFocus
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Bitget
DCOY Stock Analysis: Decoy Therapeutics Inc. Slides 7.5% to $5.8 Key Biotech Trends - Newser
Decoy Therapeutics regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia
Decoy Therapeutics Inc Azioni (DCOY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Decoy Therapeutics Inc Azioni (DCOY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | Director |
Dec 30 '25 |
Sale |
0.64 |
12 |
8 |
0 |
| HANISH ARNOLD C | Director |
Nov 20 '25 |
Buy |
0.75 |
5,000 |
3,740 |
5,015 |
| Rosenblum Mark J | Exec VP Finance, CFO |
Nov 20 '25 |
Buy |
0.80 |
20,000 |
16,000 |
20,177 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):